A phase I/II study in combination of YHI-1001 and Sorafenib in patients with advanced hepatocellular carcinoma previously untreated with systemic chemotherapy

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222078

Enrollment

164

Registered

2013-05-14

Start date

2013-05-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with advanced hepatocellular carcinoma previously untreated with systemic chemotherapy

Interventions

investigational material(s) Generic name etc : YHI-1001+Sorafenib INN of investigational material : Resminostat+Sorafenib Therapeutic category code : 429 Other antitumor agents Dosage and Administrati

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients with advanced or metastatic hepatocellular carcinoma (2)Patients with ECOG PS of 0-1 (3)Patients who can be treated with oral medications and have no gastrointestinal function disorder which is considered to affect the absorption of medications

Exclusion criteria

Exclusion criteria: (1)Patients with a history of treatment with HDAC inhibitors (2)Pregnant women and lactating mothers (3)Patients with brain metastases or suspected brain metastases based on the clinical symptoms

Design outcomes

Primary

Measure	Time frame
PI:Safety PII:Efficacy	—

Secondary

Measure	Time frame
PI:PK PII:Safety	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026